|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0013216,
umls-concept:C0021149,
umls-concept:C0023487,
umls-concept:C0023508,
umls-concept:C0039082,
umls-concept:C0040845,
umls-concept:C0205251,
umls-concept:C0332162,
umls-concept:C0392756,
umls-concept:C1274040,
umls-concept:C1518321,
umls-concept:C1843571,
umls-concept:C1850419,
umls-concept:C1970036
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2003-2-19
|
|
pubmed:abstractText |
Treatment combining ATRA and chemotherapy (CT) has improved the outcome of APL patients, by comparison with CT alone. ATRA syndrome is a life-threatening complication of ATRA treatment whose prophylaxis remains somewhat controversial. In APL93 trial, newly diagnosed APL patients </=65 years and with initial WBC counts below 5000/mm(3) were randomized between ATRA until CR achievement followed by CT (ATRA --> CT) and ATRA with early addition of CT, on day 3 of ATRA treatment (ATRA + CT). The incidence of ATRA syndrome in the ATRA --> CT arm was 18% (22/122) as compared to 9.2% (17/184) in the ATRA + CT arm (P = 0.035). In the ATRA --> CT arm, three (2.5%) patients died from ATRA syndrome, as compared to one (0.5%) in the ATRA + CT group. Early addition of chemotherapy to ATRA in newly diagnosed APL with low WBC counts significantly reduced the incidence of ATRA syndrome.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0887-6924
|
|
pubmed:author |
pubmed-author:CaillotDD,
pubmed-author:ChevretSS,
pubmed-author:ChomienneCC,
pubmed-author:CoiteuxVV,
pubmed-author:CondeEE,
pubmed-author:Cony MakhoulDD,
pubmed-author:DegosLL,
pubmed-author:DombretHH,
pubmed-author:European APL group,
pubmed-author:FenauxPP,
pubmed-author:FeyMM,
pubmed-author:GardembasMM,
pubmed-author:GardinCC,
pubmed-author:GuerciAA,
pubmed-author:LefrereFF,
pubmed-author:PrusO HOH,
pubmed-author:RemanOO,
pubmed-author:San MiguelJJ,
pubmed-author:StamatoulasAA,
pubmed-author:VekhoffAA,
pubmed-author:de BottonSS,
pubmed-author:de la SernaJJ
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
339-42
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12592333-Adult,
pubmed-meshheading:12592333-Age of Onset,
pubmed-meshheading:12592333-Antineoplastic Agents,
pubmed-meshheading:12592333-Female,
pubmed-meshheading:12592333-Humans,
pubmed-meshheading:12592333-Leukemia, Promyelocytic, Acute,
pubmed-meshheading:12592333-Leukocyte Count,
pubmed-meshheading:12592333-Leukopenia,
pubmed-meshheading:12592333-Male,
pubmed-meshheading:12592333-Middle Aged,
pubmed-meshheading:12592333-Retrospective Studies,
pubmed-meshheading:12592333-Syndrome,
pubmed-meshheading:12592333-Treatment Outcome,
pubmed-meshheading:12592333-Tretinoin
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
